^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Campath (alemtuzumab)

    i
    Other names: LDP 03, Campath-1H, LDP-03, MoAb CD52, monoclonal antibody Campath-1H, CLLS52, CLLS-52, LDP03, CLLS 52
    Company:
    Bayer, Sanofi
    Drug class:
    CD52 inhibitor
    Related drugs:
    11d
    Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Boston Children's Hospital | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • DKC1 (Dyskerin Pseudouridine Synthase 1) • ZCCHC8 (Zinc Finger CCHC-Type Containing 8) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion
    2ms
    A Unique Case of Concomitant T-Prolymphocytic Leukemia and B-Cell Acute Lymphoblastic Leukemia. (PubMed, EJHaem)
    One proposed mechanism for the development of both hematologic malignancies in this patient is the acquisition of a KMT2A rearrangement, raising the possibility of clonal evolution resulting in therapy-related or secondary leukemia. Another explanation is the presence of a common clonal stem cell progenitor harboring a JAK3 mutation.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A) • JAK3 (Janus Kinase 3)
    |
    KMT2A rearrangement
    |
    Campath (alemtuzumab)
    2ms
    Immune Disorder HSCT Protocol (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Apr 2026 | Trial primary completion date: Mar 2027 --> Apr 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab) • melphalan • fludarabine IV • thiotepa
    2ms
    TEACH: Tolerance by Engaging Antigen During Cellular Homeostasis (clinicaltrials.gov)
    P1, N=8, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed | Trial completion date: Dec 2029 --> Sep 2025
    Trial completion • Trial completion date
    |
    Campath (alemtuzumab) • prednisone • sirolimus
    2ms
    Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (clinicaltrials.gov)
    P2, N=48, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan
    2ms
    Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Case Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Campath (alemtuzumab) • sirolimus
    3ms
    Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (clinicaltrials.gov)
    P=N/A, N=57, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=30 --> 57
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • mesna • busulfan
    3ms
    Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. (PubMed, Blood Neoplasia)
    Continued studies evaluating JAK inhibitors in patients with T-PLL are warranted. This trial was registered at www.clinicaltrials.gov as #NCT03989466.
    Clinical • P1 data • Journal
    |
    JAK3 (Janus Kinase 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A) • IL2RG (Interleukin 2 Receptor Subunit Gamma)
    |
    Campath (alemtuzumab) • itacitinib (INCB039110)
    3ms
    Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Boston Children's Hospital | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • DKC1 (Dyskerin Pseudouridine Synthase 1) • ZCCHC8 (Zinc Finger CCHC-Type Containing 8) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion
    3ms
    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders (clinicaltrials.gov)
    P1/2, N=29, Recruiting, Washington University School of Medicine | Trial completion date: Apr 2031 --> Apr 2033 | Trial primary completion date: Apr 2026 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • hydroxyurea
    3ms
    NCI-2022-03571: TMLI and Alemtuzumab for Treatment of Sickle Cell Disease (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 2
    Enrollment closed • Enrollment change
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Campath (alemtuzumab) • sirolimus
    4ms
    Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases. (PubMed, Ther Adv Neurol Disord)
    The specific humoral and cellular response to vaccination can be compromised under alemtuzumab, azathioprine, cladribine, cyclophosphamide, CD19/CD20 antibodies (inebilizumab, ocrelizumab, ofatumumab, rituximab, ublituximab), dimethyl fumarate/diroximel fumarate, FcRn inhibitors (efgartigimod, rozanolixizumab), complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan), interleukin-6 receptor antibodies (tocilizumab, satralizumab), intravenous immunoglobulins, long-term steroid administration, methotrexate, mitoxantrone, mycophenolate mofetil, tacrolimus, teriflunomide, tumor necrosis factor-α blockers, and sphingosine-1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, siponimod), as well as after autologous stem cell transplantation...However, the humoral and cellular vaccination response may be impaired under immunotherapy necessitating close monitoring. Here, we provide applicable recommendations to optimize immunization for individuals receiving immunotherapy due to a neurological autoimmune disease.
    Journal
    |
    IL6R (Interleukin 6 receptor)
    |
    Rituxan (rituximab) • cyclophosphamide • methotrexate • Campath (alemtuzumab) • mitoxantrone • cladribine • Arzerra (ofatumumab) • Briumvi (ublituximab-xiiy) • fingolimod • Actemra IV (tocilizumab) • Ocrevus (ocrelizumab) • Uplizna (inebilizumab-cdon)